James Chopas Biography and Net Worth

James G. Chopas CPA is the VP, Corp. Controller & Chief Accounting Officer at Apellis Pharmaceuticals Inc.

What is James George Chopas' net worth?

The estimated net worth of James George Chopas is at least $1.56 million as of March 15th, 2024. Mr. Chopas owns 38,883 shares of Apellis Pharmaceuticals stock worth more than $1,558,042 as of June 20th. This net worth approximation does not reflect any other investments that Mr. Chopas may own. Learn More about James George Chopas' net worth.

How do I contact James George Chopas?

The corporate mailing address for Mr. Chopas and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on James George Chopas' contact information.

Has James George Chopas been buying or selling shares of Apellis Pharmaceuticals?

James George Chopas has not been actively trading shares of Apellis Pharmaceuticals during the last ninety days. Most recently, James George Chopas sold 184 shares of the business's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $56.46, for a transaction totalling $10,388.64. Following the completion of the sale, the chief accounting officer now directly owns 38,883 shares of the company's stock, valued at $2,195,334.18. Learn More on James George Chopas' trading history.

Who are Apellis Pharmaceuticals' active insiders?

Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Apellis Pharmaceuticals?

During the last twelve months, insiders at the sold shares 49 times. They sold a total of 776,863 shares worth more than $42,616,032.50. The most recent insider tranaction occured on May, 8th when insider Pascal Deschatelets sold 78,907 shares worth more than $3,341,711.45. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.

Information on this page was last updated on 5/8/2024.

James George Chopas Insider Trading History at Apellis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2024Sell184$56.46$10,388.6438,883View SEC Filing Icon  
1/22/2024Sell1,061$65.00$68,965.0039,067View SEC Filing Icon  
1/16/2024Sell864$66.81$57,723.8440,128View SEC Filing Icon  
10/23/2023Sell132$46.04$6,077.2832,680View SEC Filing Icon  
8/31/2023Sell551$41.23$22,717.7330,312View SEC Filing Icon  
See Full Table

James George Chopas Buying and Selling Activity at Apellis Pharmaceuticals

This chart shows James George Chopas's buying and selling at Apellis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $40.07
Low: $39.53
High: $41.19

50 Day Range

MA: $44.14
Low: $39.25
High: $55.73

2 Week Range

Now: $40.07
Low: $19.83
High: $92.61


802,046 shs

Average Volume

1,032,409 shs

Market Capitalization

$4.86 billion

P/E Ratio


Dividend Yield